MX376201B - Compuestos inhibidores de metaloenzima. - Google Patents

Compuestos inhibidores de metaloenzima.

Info

Publication number
MX376201B
MX376201B MX2018008105A MX2018008105A MX376201B MX 376201 B MX376201 B MX 376201B MX 2018008105 A MX2018008105 A MX 2018008105A MX 2018008105 A MX2018008105 A MX 2018008105A MX 376201 B MX376201 B MX 376201B
Authority
MX
Mexico
Prior art keywords
inhibiting compounds
metalloenzyme
metalloenzyme inhibiting
metalloenzymes
mediated
Prior art date
Application number
MX2018008105A
Other languages
English (en)
Other versions
MX2018008105A (es
Inventor
Christopher M Yates
Sammy R Shaver
William J Hoekstra
Original Assignee
Nqp 1598 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nqp 1598 Ltd filed Critical Nqp 1598 Ltd
Publication of MX2018008105A publication Critical patent/MX2018008105A/es
Publication of MX376201B publication Critical patent/MX376201B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención describe compuestos que tienen actividad moduladora de metaloenzima, y métodos para tratar enfermedades, trastornos o síntomas de los mismos mediadas por dichas metaloenzimas.
MX2018008105A 2015-12-30 2016-12-29 Compuestos inhibidores de metaloenzima. MX376201B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562273167P 2015-12-30 2015-12-30
PCT/US2016/069217 WO2017117393A1 (en) 2015-12-30 2016-12-29 Metalloenzyme inhibitor compounds

Publications (2)

Publication Number Publication Date
MX2018008105A MX2018008105A (es) 2018-11-12
MX376201B true MX376201B (es) 2025-03-07

Family

ID=59225927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008105A MX376201B (es) 2015-12-30 2016-12-29 Compuestos inhibidores de metaloenzima.

Country Status (12)

Country Link
US (1) US10464922B2 (es)
EP (1) EP3397629B1 (es)
JP (1) JP6803923B2 (es)
KR (1) KR102240920B1 (es)
CN (1) CN108779094B (es)
AU (1) AU2016380349B2 (es)
BR (1) BR112018013522A2 (es)
CA (1) CA3006469C (es)
EA (1) EA038421B1 (es)
MX (1) MX376201B (es)
TW (1) TWI623528B (es)
WO (1) WO2017117393A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2942231A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
AU2015231234B2 (en) 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
EP3119771B1 (en) 2014-03-19 2020-05-06 Mycovia Pharmaceuticals, Inc. Antifungal compound process
BR112016021257B1 (pt) 2014-03-19 2021-03-02 Viamet Pharmaceuticals (NC), Inc. 2-(2,4- difluorofenil-1,1-diflúor-1-(5-substituído-piridin-2-il)-3- (1h-tetrazol-1-il)propan-2-óis e processos para preparação e uso dos mesmos
CA2942932A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
AU2015231226B2 (en) 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
WO2015143142A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
US10399943B2 (en) 2014-03-19 2019-09-03 Mycovia Pharmaceuticals, Inc. Antifungal compound process
EP3119756B9 (en) 2014-03-19 2021-08-25 Dow AgroSciences LLC 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
KR20180052755A (ko) 2015-09-18 2018-05-18 브이피에스-3, 인크. 항진균 화합물 및 이의 제조방법
WO2019182743A1 (en) * 2018-03-20 2019-09-26 Innocrin Pharmaceuticals, Inc. Compositions for the treatment of brain tumors
WO2020077197A1 (en) 2018-10-11 2020-04-16 Innocrin Pharmaceuticals, Inc. Compositions for the treatment of brain tumors
IL307258A (en) 2021-04-05 2023-11-01 Halia Therapeutics Inc NEK7 inhibitors
CN113444131B (zh) * 2021-06-24 2022-10-21 鲁东大学 N-乙酰氨基葡萄糖类化合物及其制备方法和应用
US20250270193A1 (en) * 2021-10-20 2025-08-28 Ohio State Innovation Foundation Arylimidamides for use in treatment of cancers
CN115466227B (zh) * 2022-06-30 2024-07-19 杭州国瑞生物科技有限公司 一种3-(氯甲基)-1-甲基-1h-1,2,4-三唑盐酸盐的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
PT96059B (pt) 1989-12-04 1998-07-31 Searle & Co Sistema de camada unica para a administracao de um medicamento por via transdermica
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
DE69535486T2 (de) * 1994-06-15 2008-04-10 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclische Verbindungen verwendbar als Vasopressin- oder Oxytocin-Modulatoren
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
AUPP999799A0 (en) * 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
EP1372394A1 (en) * 2001-04-03 2004-01-02 Schering Corporation Antifungal composition with enhanced bioavailability
BR112012027308B1 (pt) * 2010-04-24 2021-07-06 Mycovia Pharmaceuticals, Inc. compostos inibidores de metaloenzima e composições compreendendo os mesmos
KR20140093610A (ko) * 2011-04-21 2014-07-28 재단법인 한국파스퇴르연구소 소염 화합물
AU2013209516A1 (en) 2012-01-20 2014-08-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
US9414596B2 (en) 2012-01-20 2016-08-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN105431418B (zh) 2013-06-12 2019-02-05 北卡罗来纳维亚梅特制药公司 金属酶抑制剂化合物
WO2015143137A1 (en) * 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process

Also Published As

Publication number Publication date
EA201891539A1 (ru) 2018-12-28
MX2018008105A (es) 2018-11-12
EP3397629A1 (en) 2018-11-07
TW201734000A (zh) 2017-10-01
KR102240920B1 (ko) 2021-04-16
AU2016380349A1 (en) 2018-06-14
KR20180099845A (ko) 2018-09-05
CN108779094B (zh) 2021-11-16
CA3006469C (en) 2023-01-10
US10464922B2 (en) 2019-11-05
TWI623528B (zh) 2018-05-11
JP6803923B2 (ja) 2020-12-23
EP3397629A4 (en) 2019-06-05
JP2019502755A (ja) 2019-01-31
US20190016700A1 (en) 2019-01-17
AU2016380349B2 (en) 2020-10-29
CA3006469A1 (en) 2017-07-06
CN108779094A (zh) 2018-11-09
EP3397629B1 (en) 2023-04-19
WO2017117393A1 (en) 2017-07-06
BR112018013522A2 (pt) 2018-12-11
EA038421B1 (ru) 2021-08-26

Similar Documents

Publication Publication Date Title
MX376201B (es) Compuestos inhibidores de metaloenzima.
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
HK1223093A1 (zh) 杀真菌组合物
EA201490030A1 (ru) Соединения, ингибирующие металлоферменты
PH12013502622A1 (en) Metalloenzyme inhibitor compounds
PH12013502624A1 (en) Metalloenzyme inhibitor compounds
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
IN2014DN06792A (es)
MX2022012386A (es) Compuestos inhibidores de metaloenzimas.
CY1120246T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
BR112018011709A2 (pt) inibidores bicíclicos de pad4
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
EA201790998A1 (ru) Иммуннорегуляторные агенты
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
UY36080A (es) Compuestos inhibidores de metaloenzima como fungicidas.
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
MX375737B (es) Imidazopirazinonas como inhibidores de pde1.
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: NQP 1598, LTD.

HC Change of company name or juridical status

Owner name: INTERDIGITAL CE PATENT HOLDINGS

FG Grant or registration